Overview of Nitazoxanida Genfar

Property	Description
Active Ingredient	Nitazoxanide
Form	Oral Tablet, Oral Suspension
Pharmacological Class	Antiprotozoal Agent, Broad-Spectrum Anti-infective
Common Use	Treatment of Infections Caused by Susceptible Parasites
Origin	Synthetic Compound (Thiazolide Class)

What Type of Medicine is Nitazoxanida Genfar?

Nitazoxanida Genfar is a prescription-only pharmaceutical preparation whose active ingredient is the synthetic compound, Nitazoxanide. This substance is primarily classified as an antiprotozoal agent and a broad-spectrum anti-infective, distinguishing it from common antibiotics. Nitazoxanide is the established prototype of the thiazolide chemical class and is characterized as an antiparasitic medication. Its general purpose is providing effective anti-infective treatment against these pathogenic organisms.

Composition and Available Forms of Nitazoxanide

The core composition of this product is the single active ingredient, Nitazoxanide, formulated for the oral administration route. The medication is supplied in two distinct pharmaceutical preparations: the tablet form and an oral suspension (prepared from a powder for reconstitution), which allows for flexible administration to both adults and children. This availability is a key differentiating factor, especially the liquid form, which often contains flavoring to facilitate acceptance by younger patients. The broad-spectrum nature of Nitazoxanide includes efficacy against a wide range of protozoa and helminths.

How Does Nitazoxanide Generally Affect Organisms?

The antiprotozoal activity of Nitazoxanide is achieved by selectively disrupting the energy pathways of the targeted infectious organisms. Once absorbed, the drug is converted into its active metabolite, Tizoxanide, which interferes with the essential anaerobic energy metabolism required for the pathogen’s survival. This distinctive mechanism of action provides the foundation for the medication's broad therapeutic benefit, allowing the body to clear the infection by stopping the organisms' ability to grow and multiply.

What side effects are possible with Nitazoxanida Genfar?

Possible side effects and safety information

The safety profile for the active ingredient, Nitazoxanide, is established through clinical trials and postmarketing surveillance, as documented by official regulatory sources like the FDA. Adverse reactions are classified according to their frequency and the system-organ class affected.

Documented Adverse Reactions

The most frequently reported side effects are generally confined to the gastrointestinal and nervous systems, although effects on other systems are also noted.

Classification	System-Organ Class	Examples of Documented Effects
Common (In clinical trials)	Gastrointestinal, Nervous System, Renal/Urinary	Abdominal pain, Nausea, Headache, Chromaturia (discolored urine)
Postmarketing/Spontaneous	Gastrointestinal, Respiratory, Skin	Diarrhea, Dizziness, Dyspnea (difficulty breathing), Rash, Urticaria

Serious Safety Constraints and Special Populations

Nitazoxanide is formally contraindicated in individuals with a known prior hypersensitivity (allergic reaction) to the drug or any of its components. This restriction is based on the potential for serious adverse reactions.

Safety considerations also apply to specific patient groups, requiring official caution in certain circumstances:

Hepatic and Renal Impairment: The pharmacokinetics of Nitazoxanide have not been fully studied in patients with severe liver or kidney impairment, necessitating careful administration.
Pediatric Use: The standard tablet formulation may be considered inappropriate for children 11 years of age and younger due to the specific dosage amount.
Drug Interaction Concern: The active metabolite is highly protein-bound (>99.9%). When co-administered with other highly protein-bound medicines that have a narrow therapeutic index, such as warfarin, monitoring is noted as necessary by regulatory labeling.

Overdose and Emergency Response

Overdose and When to Seek Help

Information regarding an overdose of Nitazoxanida Genfar (Nitazoxanide) is strictly limited in official regulatory documentation. The regulatory profile is defined by the necessary emergency response actions rather than a detailed symptom list.

Documented Overdose Findings

The official data available documents that single oral doses of up to 4000 mg were administered to healthy adult volunteers without producing significant adverse effects. This finding establishes that specific severe or life-threatening manifestations are not formally described in the overdose section of the official label. The regulatory documentation does not define specific overdose risks for particular populations, such as pediatric, geriatric, or those with underlying hepatic or renal impairment.

Immediate Emergency Actions

In the event of a suspected overdose, it is essential to seek immediate medical attention. Management guidelines require that patients be observed and provided with symptomatic and supportive treatment. Furthermore, official prescribing information states there is no specific antidote for a Nitazoxanide overdose. As a specific supportive measure, gastric lavage may be considered appropriate if the overdose occurred soon after oral administration.

Therapeutic Uses of Nitazoxanida Genfar

What Nitazoxanida Genfar Treats: Main Uses and Benefits

Nitazoxanida Genfar is primarily used to address infectious diarrheal symptoms related to physical discomfort in conditions caused by susceptible protozoa and certain helminths. This medication is prescribed to help manage diarrhea caused by organisms such as Giardia lamblia (Giardiasis) and Cryptosporidium parvum (Cryptosporidiosis), which are often associated with acute symptoms that interfere with daily functioning. It may also be applied across domains where additional symptomatic support is needed, involving other susceptible infections, including certain helminths like Ascaris lumbricoides.

The medication is generally applied in clinical settings that involve acute or unstable symptom patterns, such as Traveler's Diarrhea when a protozoal cause is suspected. This anti-infective treatment is applied in addressing symptoms that create noticeable functional strain. Its primary benefit is to support parasite clearance, which contributes to the resolution of the diarrheal illness and helps ease the overall symptom burden. It is commonly used for both adults and children, assisting with maintaining functional stability during the symptomatic phase.

Quick Fact: Relief for Infectious Diarrhea The medicine is commonly used to help with the symptom clusters related to protozoa-driven diarrheal illness and associated gastrointestinal distress.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for using Nitazoxanida Genfar (nitazoxanide) is strictly defined by regulatory documents, focusing on patient characteristics, age, and existing health conditions.

Contraindications and Exclusion Criteria

Criteria	Status
Hypersensitivity	Contraindicated (Must not be used if allergic to nitazoxanide or its ingredients).
Age (Tablets)	Not recommended for pediatric patients 11 years of age or younger (due to tablet dosage strength).
Immunologic Status	Efficacy not established for treating Cryptosporidium parvum in HIV-infected or immunodeficient patients.

Specific Population Restrictions

Pediatric Use: The tablet formulation is indicated for patients 12 years of age and older. The oral suspension formulation is generally used for children 1 year through 11 years of age, and safety/efficacy has not been established in children younger than 1 year.
Hepatic or Renal Impairment: The pharmacokinetics of nitazoxanide have not been studied in patients with compromised liver or kidney function; therefore, the drug must be administered with caution in these groups.
Pregnancy and Lactation: There are no controlled studies in human pregnancy available. It is not known whether the drug or its active metabolites are excreted into human milk, and caution is advised for nursing women.

What should I know about interactions with other medicines?

Nitazoxanida Genfar’s official interaction profile is primarily determined by the pharmacokinetic behavior of its active metabolite, Tizoxanide. This metabolite is highly bound to plasma protein (greater than 99.9%), which underpins its documented interaction patterns.

Drug–Drug and Substance Interactions

Exposure Modification (Protein Binding): The regulatory documentation highlights the potential for competition for protein binding sites when co-administered with other highly plasma protein-bound medicines that possess narrow therapeutic indices. The specific example cited in official labels is Warfarin. This competitive binding may result in altered plasma concentrations of the co-administered drug.

Metabolic Pathways: The regulatory profile states that no significant interaction is expected with drugs that are metabolized by or inhibit Cytochrome P450 (CYP) enzymes, limiting the scope of metabolic drug-drug interactions.

Food and Timing Requirements: A key constraint requires the medicine to be taken with food. This condition is mandatory because co-administration with meals significantly increases the oral bioavailability of Tizoxanide, impacting the overall drug exposure (increasing the AUC and Cmax).

Population-Specific Notes: Regulatory information indicates that the pharmacokinetics of Nitazoxanide have not been studied in individuals with compromised renal function impairment or hepatic and biliary disease.

Mechanism of Action

The active component, Nitazoxanide, acts through its active metabolite, Tizoxanide, by disrupting multiple essential biological systems within susceptible pathogens. The primary antiprotozoal mechanism involves Tizoxanide acting as a non-competitive inhibitor of the enzyme Pyruvate: Ferredoxin/Flavodoxin Oxidoreductase (PFOR). This enzyme is crucial for the electron transfer required for ATP synthesis in protozoa and anaerobic bacteria. The disruption of this core metabolic pathway results in the pathogen's loss of cellular viability and proliferation. Against helminths, the drug employs a dual mechanism: it inhibits Glutathione-S-transferase (GST), which compromises the worm’s cellular defenses, and modulates chloride ion channels in its nervous system. These combined actions induce neuromuscular paralysis and subsequent loss of viability. Furthermore, Tizoxanide functions as an inducer of Type I Interferons (IFN) in host cells, engaging the body's innate immune pathways and establishing a protective antiviral state that suppresses viral replication.

Dosage and Administration Information

How to Use Nitazoxanida Genfar

This section outlines the general principles and administration guidelines for Nitazoxanida (Nitazoxanide), focusing on dose, frequency, and conditions of use.

Administration Protocol

Nitazoxanida is an oral-only medication. The administration protocol is structured around a fixed, short-term course that requires consistent timing with food to ensure proper absorption of the active metabolite, Tizoxanide. The total duration of use for the approved indications is three days.

Feature	Instruction
Route	Oral (by mouth).
Duration	3 days total course.
Timing	Must be administered with food (to enhance systemic exposure).
Frequency	Twice daily (every 12 hours).

Standard Dosing by Age and Form

Dosage is strictly determined by age, and the two available formulations—the 500 mg tablet and the 100 mg/5 mL oral suspension—are not considered interchangeable.

Population	Dose per Administration	Key Restriction
Adults (12+ years)	500 mg per dose.	None (Tablets or Suspension).
Children 4–11 years	200 mg per dose (10 mL suspension).	500 mg tablets are prohibited in this age group.
Young Children 1–3 years	100 mg per dose (5 mL suspension).	Use of tablets is prohibited.

Procedural Instructions

When the oral suspension is used, the container requires vigorous shaking before each dose to ensure uniform concentration. The protocol for use in patients with renal or hepatic impairment has not been formally studied and, therefore, specific dosage adjustment guidance is unavailable.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nitazoxanida Genfar

Evidence for Use in Cryptosporidiosis

The research base for this medicine against infection by Cryptosporidium parvum (Cryptosporidiosis) was evaluated in Randomized Controlled Trials (RCTs). This research examined outcomes related to physical discomfort, focusing on diarrheal symptom changes, and parasitological outcomes, measured by the absence of the organism in stool samples. These core trials was evaluated in immunocompetent children (aged 1 year and older) and immunocompetent adults and adolescents. The findings describe patterns observed in the studies where parasite clearance and changes in outcomes related to physical discomfort were observed in these primary study groups. Research describes changes measured during the study period that were studied for both clinical evaluation and the clearing of the organism.

Evidence for Use in Giardiasis

Evidence for this medicine against infection by Giardia lamblia was evaluated in Randomized Controlled Trials (RCTs). Many of these trials were Active-Controlled, meaning they were designed to evaluate the medicine alongside an approved anti-parasitic agent for Giardiasis. This research examined outcomes related to functional imbalance, such as acute diarrheal episodes, and also parasitological outcomes, tracking the absence of G. lamblia in stool. Studies report how symptoms evolved in the observed populations, and findings generally described patterns of parasite clearance and outcomes related to episodic or acute changes that were measured during the study period.

Evidence in Special Populations and Subgroups

The core research base focused on Immunocompetent Children (starting at age 1) and Immunocompetent Adults and Adolescents. Data for certain groups remain insufficient, most notably for individuals with compromised immune systems. Studies exploring its activity in immunodeficient patients with Cryptosporidium parvum contribute to the broader evidence landscape, but certainty remains low. The results apply only to the populations studied in the core trials. Long-term effects are not fully established by the existing pivotal data, as follow-up durations were limited to the immediate post-treatment period.

Evidence Gaps and Research Uncertainty

The official research record highlights several evidence gaps and areas where certainty remains low. The most significant limitation is the lack of conclusive evidence for use in immunodeficient patients for either Cryptosporidiosis or Giardiasis. Subgroup findings in this area are uncertain. The research provides insight into short-term changes and findings reflect group patterns. Comparative evidence is lacking for many of the secondary parasitic infections, and the evidence quality varies across studies for non-core indications.

Key Studies & References Nitazoxanide for the treatment of Giardia duodenalis infection: A comparative trial with secnidazole

Frequently Asked Questions (FAQ)

Common questions about Nitazoxanida Genfar (FAQ)

Q: Is Nitazoxanida Genfar used for more than one type of infection?

The active ingredient in Nitazoxanida Genfar is classified as a broad-spectrum anti-infective. While the main official approvals are for specific protozoal infections (Giardia and Cryptosporidium), research related to its chemical class includes activity against various types of parasites, including certain helminths (worms), and some anaerobic bacteria.

Q: Does Nitazoxanida Genfar treat diarrhea caused by viruses or bacteria?

The official approved uses for this medicine are specifically for diarrhea caused by the parasites Cryptosporidium parvum and Giardia lamblia. While the drug’s mechanism of action suggests activity against certain anaerobic bacteria and some studies have examined its effect on host immune response, its primary regulatory approval is limited to the defined parasitic indications.

Q: Is a headache a common side effect of Nitazoxanida Genfar?

Yes. According to the official regulatory documents and reports from clinical trials, headache is listed as one of the most common adverse reactions reported by people using the active ingredient, nitazoxanide.

Q: Can Nitazoxanida Genfar be taken while pregnant?

Official labeling indicates that there are no adequate and well-controlled studies of the active ingredient in pregnant women. Animal studies did not suggest harm to the developing fetus, but the guidance states that the drug's use during pregnancy requires considering the potential benefit against any potential risk.

Q: Is Nitazoxanida Genfar considered safe to use while breastfeeding?

It is not known whether the active ingredient or its breakdown products pass into human breast milk. Due to this lack of data, official guidance indicates that caution is generally advised when considering its use in nursing women.

Q: Does having liver or kidney problems affect the use of Nitazoxanida Genfar?

Official information states that the way the body processes the drug has not been fully studied in people with compromised liver or kidney function. Therefore, regulatory caution is advised when the medicine is administered to patients with hepatic (liver), biliary, or renal (kidney) disease.

Q: What happens if a dose of Nitazoxanida Genfar is missed?

If an individual misses a dose, official patient counseling information suggests taking the dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. It is generally advised that a double dose should not be taken to make up for a missed dose.

Q: Can this medication be used for Traveler's diarrhea?

The medicine's approved uses address diarrhea caused by specific parasitic organisms, Giardia lamblia and Cryptosporidium parvum. While these organisms can be among the causes of Traveler’s Diarrhea, regulatory documents do not list the general condition 'Traveler’s Diarrhea' as a standalone approved indication.

Q: Is Nitazoxanida Genfar the same as the drug Alinia?

Yes, the active component of Nitazoxanida Genfar is nitazoxanide. This is the same active pharmaceutical ingredient found in the brand-name medicine Alinia, making Nitazoxanida Genfar a generic equivalent.

Q: Are there studies on the use of Nitazoxanida Genfar in people with a weakened immune system?

Studies have been conducted in people with weakened immune systems, but official documentation notes that the efficacy of the drug has not been definitively established for treating certain parasitic infections in HIV-infected or immunocompromised patients. Findings in this population remain uncertain.

Q: Does Nitazoxanida Genfar have a strong interaction with alcohol?

Based on official drug interaction databases and labeling, no specific interaction between the active ingredient, nitazoxanide, and alcohol is listed.

Q: Can Nitazoxanida Genfar cause dizziness or fatigue?

Official safety profiles indicate that dizziness has been documented as an adverse reaction in post-marketing reports. However, fatigue is not specifically listed as one of the common or spontaneous adverse effects in the official safety profile provided in regulatory documents.

Q: What kind of research has been done on Nitazoxanida Genfar besides its main indication?

Research has investigated the drug's activity beyond its main parasitic indications, including its effects against other types of helminths (worms) and its unique mechanism that can activate the host immune system. This has led to studies exploring its potential as a broad-spectrum antiviral agent that suppresses viral replication.

Q: What is the difference between a parasitic cure and a clinical cure in studies?

Clinical trials for the medicine define a parasitological outcome or cure as the absence of the pathogenic organism in stool samples after treatment. A clinical outcome or cure refers to the resolution or measurable improvement of physical symptoms, such as the acute episodes of diarrhea.

Q: What should be done if symptoms do not improve after finishing the course of medicine?

General patient counseling information describes that if the condition or its symptoms persist or worsen after completing the course, consulting a healthcare provider is noted as appropriate.

Q: Can this medicine be used to treat 'worms' or other helminths?

The mechanism of action of the active ingredient is described as active against certain helminthic organisms, which is supported by research. While the primary regulatory approval focuses on protozoal infections, the drug’s chemical classification suggests activity against a range of helminthic organisms.

Q: Is there any risk of drug-induced liver injury with Nitazoxanida Genfar?

The official label advises caution for people with pre-existing hepatic disease because the drug's processing has not been formally studied in this group. Regulatory documents note that increases in a liver enzyme (ALT/SGPT) were reported in a small percentage of patients during clinical trials, though this was not frequently observed.

Q: Does Nitazoxanida Genfar interact with herbal or nutritional supplements?

Official patient information generally advises telling a healthcare provider about all substances being used. This includes prescription medicines, over-the-counter products, vitamins, mineral supplements, and herbal products, to allow the professional to check for potential interactions.

Q: What are the concerns about using Nitazoxanida Genfar in people with HIV or AIDS?

The key concern noted in official documentation is that the efficacy of the drug has not been established for treating Cryptosporidium parvum infection in individuals who are immunocompromised, including those with HIV/AIDS. Therefore, clinical caution is specifically noted for this population.

How should Nitazoxanida Genfar be stored and disposed of?

Nitazoxanide tablets must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from excess heat and moisture and kept in the container it was provided in, with the lid tightly closed.

Child Safety and Stability

The product must be stored out of the reach of children. For the oral suspension form, once the product is mixed, it has a limited stability period and must be discarded after 7 days.

Disposal

Unused or expired Nitazoxanide should be disposed of properly according to local regulations. Patients are instructed to consult a healthcare professional regarding the safe disposal method for any leftover medication.

Nitazoxanida Genfar